Dr Munir: What Drives Frontline CLL Treatment Decisions Today?

In an interview with Targeted Oncology at the 2026 European Hematology Association (EHA) Congress, Talha Munir, MBChB, PhD, of Leeds Teaching Hospitals NHS Trust, discussed how the expanding treatment landscape is shaping frontline decision-making for patients with chronic lymphocytic leukemia (CLL).

With multiple highly effective targeted regimens now available, Munir emphasized that selecting frontline therapy has become increasingly individualized. Rather than relying on a single clinical factor, treatment decisions should incorporate disease genomics, patient comorbidities, toxicity profiles, and patient preferences. He noted that fixed-duration venetoclax (Venclexta)-based regimens have demonstrated excellent efficacy for many patients, while continuous Bruton tyrosine kinase (BTK) inhibitor therapy remains an important option in specific clinical settings.

Munir highlighted several patient characteristics that may help guide treatment selection. For patients with IGHV-mutated disease and no significant infectious comorbidities, fixed-duration venetoclax plus obinutuzumab (Gazyva) represents an effective approach, although continuous therapy also produces favorable outcomes. Conversely, he suggested that patients with TP53-mutated disease continue to derive substantial benefit from continuous BTK inhibitor therapy, while patients with unmutated IGHV may be well suited for a BTK inhibitor plus BCL-2 inhibitor combination. He also stressed the importance of considering treatment-related toxicities, noting that recurrent infections or underlying cardiac disease may influence regimen selection.

Looking ahead, Munir said he is eager to see additional data evaluating fixed-duration strategies with second-generation BTK inhibitors, as well as studies investigating minimal residual disease (MRD)-adapted treatment approaches. These evolving strategies may help further personalize therapy by tailoring treatment duration according to patient response while maintaining durable disease control.

Ultimately, Munir underscored that modern frontline CLL management should focus on matching the right targeted therapy to the right patient, while moving away from chemoimmunotherapy in routine clinical practice.